Frequently Asked Questions
The market is segmented based on , By Strength (5mg, 10mg, 11mg, and 22mg), Drug Class (Antirheumatic, Janus Kinase Inhibitor, and Immunosuppressant), Application (Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, and Others), Demographic (Adult, Pediatric, Geriatric), Dosage Form (Tablet, Solution, Tablet, Extended Release, and Others), Route of Administration (Oral and Others), End-Users (Clinic, Hospital, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) - Industry Trends and Forecast to 2030.
.
The Global Tofacitinib Market size was valued at USD 2.34 USD Billion in 2022.
The Global Tofacitinib Market is projected to grow at a CAGR of 4.7% during the forecast period of 2023 to 2030.
The major players operating in the market include Beacon Pharmaceuticals Limited, Pfizer , Globe Pharmaceuticals, Delta Pharma Limited, DRUG INTERNATIONAL LTD, Mediconlife, Dolphin Pharma, Lancer Therapeuticals, Aprazer, Glenmark Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd, Shandong Octagon Chemicals Limited, APINO PHARMA CO., Zydus Cadila, Beijing Mesochem Technology Co., Olon S.p.A, Unichem Laboratories, Esteve Química.
The market report covers data from the U.S., Canada, Mexico, Brazil, Argentina, Peru, rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, rest of Middle East and Africa.
